Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation

Incyte is encountering significant challenges in its efforts to diversify its pipeline and reduce its reliance on the blockbuster drug Jakafi. This article appears to be part of a series tracking the company’s transition from being heavily dependent on a single product to becoming a more diversified pharmaceutical entity. It looks into the growing pains associated with this strategic shift.